| Overview |
| bsm-61821r |
| RING2 Recombinant Antibody |
| WB, IHC-P, IHC-F, IF, Flow-Cyt, ICC/IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human RING2 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 6045 |
| Q99496 |
| Nucleus |
| BAP1; DING; BAP-1; HIPI3; RING2; RING1B. |
| Acts as the main E3 ubiquitin ligase on histone H2A of the PRC1 complex, while RING1 may rather act as a modulator of RNF2/RING2 activity (Probable). Association with the chromosomal DNA is cell-cycle dependent. In resting B- and T-lymphocytes, interaction with AURKB leads to block its activity, thereby maintaining transcription in resting lymphocytes.Also acts as a negative regulator of autophagy by mediating ubiquitination of AMBRA1, leading to its subsequent degradation. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF |
|
| Flow-Cyt |
1ug/Test |
| ICC/IF |
1:50-100 |
Powered by Bioz